MSH2 and colorectal carcinoma: Similarly, path_MSH2 carriers had a cumulative incidence of metachronous CRC of 65.4% (95% c.i. 48.7% to 81.5%) after segmental resection and 14.7% (95% c.i. 5.0% to 39.0%) after extended resection.